|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61P 31/14 | |
| A61K 38/06 | |||
| A61K 38/07 | |||
| A61K 38/08 | |||
| C07K 5/08 | |||
| C07K 5/10 | |||
| C07K 5/12 |
| (11) | Patento numeris | 2540349 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12181533.6 |
| Europos patento paraiškos padavimo data | 2009-07-17 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-01-02 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-02-12 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 135559 P | 2008-07-22 | US |
| (72) |
Harper, Steven, IT
Summa, Vincenzo, IT
Liverton, Nigel J., US
McCauley, John A., US
|
| (73) |
Merck Sharp & Dohme Corp.,
126 East Lincoln Avenue, Rahway, NJ 07065,
US
MSD Italia S.r.l., Via Vitorchiano, 151, 00189 Rome, IT |
| (54) | PHARMACEUTICAL COMPOSITIONS COMPRISING A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR |
| PHARMACEUTICAL COMPOSITIONS COMPRISING A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR |